The on-going work is aimeding to validate biomarkers capable of predicting treatment response of cancer cells to combinational drug treatment. , We are use the data from genomic data and next generation sequencing data to do the bioinformatic analysis. This will enable us to obtain the signatures of the bimarkers.
The next-generation sequencing has applied to the cells that are well suited. We have data generate that are comprehensive transcriptome profiles from cancer cells. The NGS data will need to be analyzed.
We are using the cancer cell lines and cancer line-derived tumor spheriods to test the effects of the anticancer drugs in combination on the cancer growth and invasivness.